Morgan Stanley
BIB icon

Morgan Stanley’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Morgan Stanley’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$156 Hold
1
– – ﹤0.01% 7728
2025
Q4 		$125 Hold
1
– – ﹤0.01% 7681
2025
Q3 		$99 Sell
1
-87
-99% -$4.68K ﹤0.01% 7683
2025
Q2 		$4.05K Buy
88
+22
+33% +$969 ﹤0.01% 7087
2025
Q1 		$3.19K Sell
66
-131
-66% -$7.02K ﹤0.01% 7089
2024
Q4 		$9.99K Sell
197
-611
-76% -$36.2K ﹤0.01% 6800
2024
Q3 		$51.5K Buy
808
+101
+14% +$6.52K ﹤0.01% 6214
2024
Q2 		$41.9K Sell
707
-277
-28% -$15.3K ﹤0.01% 6223
2024
Q1 		$56.6K Sell
984
-780
-44% -$45.2K ﹤0.01% 6167
2023
Q4 		$101K Buy
1,764
+1,347
+323% +$63.2K ﹤0.01% 6159
2023
Q3 		$20K Buy
417
+47
+13% +$2.42K ﹤0.01% 6487
2023
Q2 		$19.2K Sell
370
-23
-6% -$1.27K ﹤0.01% 6579
2023
Q1 		$21.3K Buy
393
+252
+179% +$14.2K ﹤0.01% 6607
2022
Q4 		$8.14K Sell
141
-249
-64% -$14K ﹤0.01% 7004
2022
Q3 		$19K Buy
390
+132
+51% +$7.04K ﹤0.01% 6813
2022
Q2 		$12K Sell
258
-125
-33% -$6.36K ﹤0.01% 7158
2022
Q1 		$24K Sell
383
-929
-71% -$57K ﹤0.01% 7066
2021
Q4 		$107K Sell
1,312
-390
-23% -$33.4K ﹤0.01% 6398
2021
Q3 		$161K Sell
1,702
-621
-27% -$62.8K ﹤0.01% 6106
2021
Q2 		$229K Buy
2,323
+1,732
+293% +$151K ﹤0.01% 5945
2021
Q1 		$49K Sell
591
-605
-51% -$57.1K ﹤0.01% 6360
2020
Q4 		$103K Sell
1,196
-820
-41% -$63.5K ﹤0.01% 5897
2020
Q3 		$141K Sell
2,016
-361
-15% -$25.6K ﹤0.01% 5270
2020
Q2 		$173K Sell
2,377
-1,947
-45% -$124K ﹤0.01% 5140
2020
Q1 		$200K Buy
4,324
+1,712
+66% +$95.4K ﹤0.01% 4864
2019
Q4 		$161K Buy
2,612
+1,320
+102% +$70.4K ﹤0.01% 5490
2019
Q3 		$55K Sell
1,292
-582
-31% -$27.6K ﹤0.01% 5685
2019
Q2 		$97K Buy
1,874
+1,770
+1,702% +$88.1K ﹤0.01% 5336
2019
Q1 		$6K Sell
104
-1,169
-92% -$63K ﹤0.01% 6285
2018
Q4 		$53K Sell
1,273
-4,273
-77% -$223K ﹤0.01% 5746
2018
Q3 		$386K Buy
5,546
+4,764
+609% +$311K ﹤0.01% 5133
2018
Q2 		$45K Sell
782
-3,433
-81% -$187K ﹤0.01% 5936
2018
Q1 		$232K Buy
4,215
+2,253
+115% +$135K ﹤0.01% 5409
2017
Q4 		$110K Buy
1,962
+249
+15% +$14K ﹤0.01% 5607
2017
Q3 		$105K Sell
1,713
-6,462
-79% -$367K ﹤0.01% 5564
2017
Q2 		$436K Buy
8,175
+2,320
+40% +$113K ﹤0.01% 4891
2017
Q1 		$283K Sell
5,855
-9,696
-62% -$451K ﹤0.01% 5141
2016
Q4 		$621K Buy
15,551
+11,047
+245% +$472K ﹤0.01% 4791
2016
Q3 		$218K Buy
4,504
+4,326
+2,430% +$206K ﹤0.01% 4974
2016
Q2 		$7K Sell
178
-3,614
-95% -$156K ﹤0.01% 6142
2016
Q1 		$155K Sell
3,792
-4,194
-53% -$185K ﹤0.01% 5112
2015
Q4 		$571K Buy
7,986
+5,733
+254% +$383K ﹤0.01% 4436
2015
Q3 		$131K Sell
2,253
-4,792
-68% -$408K ﹤0.01% 5296
2015
Q2 		$637K Sell
7,045
-11,381
-62% -$979K ﹤0.01% 4527
2015
Q1 		$1.46M Sell
18,426
-9,174
-33% -$680K ﹤0.01% 3843
2014
Q4 		$1.73M Buy
27,600
+13,450
+95% +$789K ﹤0.01% 3687
2014
Q3 		$736K Buy
14,150
+12,332
+678% +$598K ﹤0.01% 4301
2014
Q2 		$84K Buy
1,818
+1,138
+167% +$44.9K ﹤0.01% 5569
2014
Q1 		$27K Buy
680
+200
+42% +$9.08K ﹤0.01% 5884
2013
Q4 		$18K Buy
+480
New +$16K ﹤0.01% 5894

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return

Morgan Stanley's BIB Position: Q1 2026 in Review

Morgan Stanley held its ProShares Ultra NASDAQ Biotechnology (BIB) position steady in Q1 2026 at 1 share worth $156. The position accounts for ﹤0.01% of the portfolio, ranked #7728.

Morgan Stanley first reported a position in BIB in Q4 2013 and has held it in 50 quarters since. The position peaked at $1.73M in Q4 2014. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Morgan Stanley held 1 share of ProShares Ultra NASDAQ Biotechnology worth $156 as of Q1 2026.
  • Morgan Stanley left its ProShares Ultra NASDAQ Biotechnology share count unchanged in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7728 holding.
  • Morgan Stanley first reported a position in ProShares Ultra NASDAQ Biotechnology in Q4 2013 and has held it in 50 quarters since.
  • Morgan Stanley's ProShares Ultra NASDAQ Biotechnology position peaked at $1.73M in Q4 2014.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.